T. Rowe Price Associates
NERV icon

T. Rowe Price Associates’s Minerva Neurosciences NERV Stock Holding History

T. Rowe Price Associates’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-7,038
Closed -$98K – 3026
2021
Q3 		$98K Hold
7,038
– – ﹤0.01% 2851
2021
Q2 		$131K Sell
7,038
-338
-5% -$7.28K ﹤0.01% 2808
2021
Q1 		$172K Buy
+7,376
New +$184K ﹤0.01% 2722
2020
Q2 		– Sell
-120,076
Closed -$5.78M – 2526
2020
Q1 		$5.78M Sell
120,076
-34,523
-22% -$2.08M ﹤0.01% 1317
2019
Q4 		$8.79M Sell
154,599
-6,143
-4% -$271K ﹤0.01% 1332
2019
Q3 		$9.97M Sell
160,742
-24,483
-13% -$1.39M ﹤0.01% 1294
2019
Q2 		$8.34M Sell
185,225
-11,506
-6% -$576K ﹤0.01% 1345
2019
Q1 		$12.4M Buy
196,731
+9,650
+5% +$580K ﹤0.01% 1288
2018
Q4 		$10.1M Sell
187,081
-28
-0% -$2.05K ﹤0.01% 1302
2018
Q3 		$18.8M Sell
187,109
-4,015
-2% -$302K ﹤0.01% 1251
2018
Q2 		$12.6M Sell
191,124
-17,621
-8% -$1.07M ﹤0.01% 1303
2018
Q1 		$10.4M Buy
208,745
+231
+0.1% +$11.1K ﹤0.01% 1325
2017
Q4 		$10.1M Buy
208,514
+175
+0.1% +$8.68K ﹤0.01% 1342
2017
Q3 		$12.7M Sell
208,339
-29,918
-13% -$1.72M ﹤0.01% 1300
2017
Q2 		$16.9M Buy
238,257
+162,089
+213% +$10.5M ﹤0.01% 1225
2017
Q1 		$4.94M Buy
76,168
+1,049
+1% +$81.5K ﹤0.01% 1431
2016
Q4 		$7.06M Sell
75,119
-4,937
-6% -$504K ﹤0.01% 1378
2016
Q3 		$9.04M Buy
+80,056
New +$7.77M ﹤0.01% 1336

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SEI Investments
SEI Investments Oaks, Pennsylvania $108B AUM 26.14% 1-Year Est. Return

T. Rowe Price Associates's NERV Position: Q4 2021 in Review

T. Rowe Price Associates sold out of Minerva Neurosciences (NERV) in Q4 2021, closing a stake of 7,038 shares — an estimated $98K sold.

T. Rowe Price Associates first reported a position in NERV in Q3 2016 and held it in 18 quarters. The position peaked at $18.8M in Q3 2018. 35 funds tracked by Wall St. Rank hold NERV as of Q4 2021.

  • T. Rowe Price Associates reported no remaining Minerva Neurosciences position as of Q4 2021 after selling out during the quarter.
  • T. Rowe Price Associates sold 7,038 Minerva Neurosciences shares in Q4 2021, an estimated $98K.
  • T. Rowe Price Associates first reported a position in Minerva Neurosciences in Q3 2016 and held it in 18 quarters.
  • T. Rowe Price Associates's Minerva Neurosciences position peaked at $18.8M in Q3 2018.
  • 35 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q4 2021.

Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.